MNOV
Price
$1.29
Change
-$0.05 (-3.73%)
Updated
Sep 5 closing price
Capitalization
63.27M
68 days until earnings call
NEVPF
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Jan 23 closing price
Capitalization
45.13M
Interact to see
Advertisement

MNOV vs NEVPF

Header iconMNOV vs NEVPF Comparison
Open Charts MNOV vs NEVPFBanner chart's image
Medicinova
Price$1.29
Change-$0.05 (-3.73%)
Volume$65.36K
Capitalization63.27M
Abliva AB
Price$0.03
Change-$0.00 (-0.00%)
Volume$58.9K
Capitalization45.13M
MNOV vs NEVPF Comparison Chart in %
Loading...
MNOV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNOV vs. NEVPF commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNOV is a Hold and NEVPF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (MNOV: $1.29 vs. NEVPF: $0.03)
Brand notoriety: MNOV and NEVPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNOV: 120% vs. NEVPF: 100%
Market capitalization -- MNOV: $63.27M vs. NEVPF: $45.13M
MNOV [@Biotechnology] is valued at $63.27M. NEVPF’s [@Biotechnology] market capitalization is $45.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNOV’s FA Score shows that 0 FA rating(s) are green whileNEVPF’s FA Score has 0 green FA rating(s).

  • MNOV’s FA Score: 0 green, 5 red.
  • NEVPF’s FA Score: 0 green, 5 red.
According to our system of comparison, NEVPF is a better buy in the long-term than MNOV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNOV’s TA Score shows that 5 TA indicator(s) are bullish.

  • MNOV’s TA Score: 5 bullish, 3 bearish.

Price Growth

MNOV (@Biotechnology) experienced а -1.53% price change this week, while NEVPF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

MNOV is expected to report earnings on Nov 13, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNOV($63.3M) has a higher market cap than NEVPF($45.1M). NEVPF YTD gains are higher at: -22.222 vs. MNOV (-38.571). MNOV has higher annual earnings (EBITDA): -13.28M vs. NEVPF (-87.99M). MNOV (34.3M) and NEVPF (32.7M) have equal amount of cash in the bank . MNOV has higher revenues than NEVPF: MNOV (135K) vs NEVPF (0).
MNOVNEVPFMNOV / NEVPF
Capitalization63.3M45.1M140%
EBITDA-13.28M-87.99M15%
Gain YTD-38.571-22.222174%
P/E RatioN/AN/A-
Revenue135K0-
Total Cash34.3M32.7M105%
Total Debt302KN/A-
FUNDAMENTALS RATINGS
MNOV vs NEVPF: Fundamental Ratings
MNOV
NEVPF
OUTLOOK RATING
1..100
940
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
90
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
7841
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
1517

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNOV's Valuation (67) in the Biotechnology industry is in the same range as NEVPF (90) in the null industry. This means that MNOV’s stock grew similarly to NEVPF’s over the last 12 months.

MNOV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NEVPF (100) in the null industry. This means that MNOV’s stock grew similarly to NEVPF’s over the last 12 months.

MNOV's SMR Rating (96) in the Biotechnology industry is in the same range as NEVPF (99) in the null industry. This means that MNOV’s stock grew similarly to NEVPF’s over the last 12 months.

NEVPF's Price Growth Rating (41) in the null industry is somewhat better than the same rating for MNOV (78) in the Biotechnology industry. This means that NEVPF’s stock grew somewhat faster than MNOV’s over the last 12 months.

NEVPF's P/E Growth Rating (100) in the null industry is in the same range as MNOV (100) in the Biotechnology industry. This means that NEVPF’s stock grew similarly to MNOV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNOVNEVPF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
15%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
14%
Advances
ODDS (%)
Bullish Trend 3 days ago
70%
N/A
Declines
ODDS (%)
Bearish Trend 25 days ago
85%
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MNOV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CURLF2.850.05
+1.79%
Curaleaf Hldgs Inc.
DLAKY8.810.14
+1.67%
Deutsche Lufthansa AG
ACCFF2.41N/A
N/A
Accord Financial Corp.
CNLPM32.65N/A
N/A
Connecticut Light & Power Co. (The)
MRPMF0.04N/A
N/A
MARCO POLO MARINE LTD.

MNOV and

Correlation & Price change

A.I.dvisor tells us that MNOV and TIL have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MNOV and TIL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNOV
1D Price
Change %
MNOV100%
-4.03%
TIL - MNOV
28%
Poorly correlated
+3.89%
NEVPF - MNOV
24%
Poorly correlated
N/A
IMA - MNOV
23%
Poorly correlated
-5.80%
ALT - MNOV
23%
Poorly correlated
+6.18%
XBIO - MNOV
22%
Poorly correlated
-0.17%
More

NEVPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NEVPF has been loosely correlated with CELC. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NEVPF jumps, then CELC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NEVPF
1D Price
Change %
NEVPF100%
N/A
CELC - NEVPF
61%
Loosely correlated
+2.23%
ADAP - NEVPF
56%
Loosely correlated
-19.61%
YMAB - NEVPF
56%
Loosely correlated
+0.12%
VYNE - NEVPF
52%
Loosely correlated
-3.64%
THAR - NEVPF
51%
Loosely correlated
-7.77%
More